{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:58:16Z","timestamp":1786982296082,"version":"build-2736575974"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2022,8,22]],"date-time":"2022-08-22T00:00:00Z","timestamp":1661126400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,8,22]],"date-time":"2022-08-22T00:00:00Z","timestamp":1661126400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100014434","name":"Irving Medical Center, Columbia University","doi-asserted-by":"publisher","award":["Department of Anesthesiology"],"award-info":[{"award-number":["Department of Anesthesiology"]}],"id":[{"id":"10.13039\/100014434","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1007\/s12185-022-03437-2","type":"journal-article","created":{"date-parts":[[2022,8,22]],"date-time":"2022-08-22T11:06:27Z","timestamp":1661166387000},"page":"937-946","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Plasma biomarkers associated with survival and thrombosis in hospitalized COVID-19 patients"],"prefix":"10.1007","volume":"116","author":[{"given":"David","family":"Cabrera-Garcia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8980-9476","authenticated-orcid":false,"given":"Andrea","family":"Miltiades","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Yim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha","family":"Parsons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katerina","family":"Elisman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Taghi","family":"Mansouri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gebhard","family":"Wagener","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil L.","family":"Harrison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,8,22]]},"reference":[{"key":"3437_CR1","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1016\/S0140-6736(20)30628-0","volume":"395","author":"P Mehta","year":"2020","unstructured":"Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020;395:1033\u20134.","journal-title":"Lancet"},{"key":"3437_CR2","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1038\/s41591-020-1051-9","volume":"26","author":"DM Del Valle","year":"2020","unstructured":"Del Valle DM, Kim-Schulze S, Huang H-H, Beckmann ND, Nirenberg S, Wang B, et al. An inflammatory cytokine signature predicts COVID-19 severity and survival. Nat Med. 2020;26:1636\u201343.","journal-title":"Nat Med"},{"key":"3437_CR3","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1007\/s10238-020-00648-x","volume":"20","author":"M Gavriatopoulou","year":"2020","unstructured":"Gavriatopoulou M, Korompoki E, Fotiou D, Ntanasis-Stathopoulos I, Psaltopoulou T, Kastritis E, et al. Organ-specific manifestations of COVID-19 infection. Clin Exp Med. 2020;20:493\u2013506.","journal-title":"Clin Exp Med"},{"key":"3437_CR4","doi-asserted-by":"publisher","first-page":"2950","DOI":"10.1016\/j.jacc.2020.04.031","volume":"75","author":"B Bikdeli","year":"2020","unstructured":"Bikdeli B, Madhavan MV, Jimenez D, Chuich T, Dreyfus I, Driggin E, et al. COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-up. J Am Coll Cardiol. 2020;75:2950\u201373.","journal-title":"J Am Coll Cardiol"},{"key":"3437_CR5","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.thromres.2020.04.013","volume":"191","author":"FA Klok","year":"2020","unstructured":"Klok FA, Kruip MJHA, van der Meer NJM, Arbous MS, Gommers DAMPJ, Kant KM, et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res. 2020;191:145\u20137.","journal-title":"Thromb Res"},{"key":"3437_CR6","doi-asserted-by":"publisher","first-page":"10464","DOI":"10.1038\/s41598-021-89967-x","volume":"11","author":"A Polimeni","year":"2021","unstructured":"Polimeni A, Leo I, Spaccarotella C, Mongiardo A, Sorrentino S, Sabatino J, et al. Differences in coagulopathy indices in patients with severe versus non-severe COVID-19: a meta-analysis of 35 studies and 6427 patients. Sci Rep. 2021;11:10464.","journal-title":"Sci Rep"},{"key":"3437_CR7","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1177\/1358863X20932640","volume":"25","author":"ME Colling","year":"2020","unstructured":"Colling ME, Kanthi Y. COVID-19-associated coagulopathy: an exploration of mechanisms. Vasc Med. 2020;25:471\u20138.","journal-title":"Vasc Med"},{"key":"3437_CR8","doi-asserted-by":"publisher","first-page":"e7","DOI":"10.1097\/TA.0000000000002963","volume":"90","author":"DJ Roh","year":"2020","unstructured":"Roh DJ, Eiseman K, Kirsch H, Yoh N, Boehme A, Agarwal S, et al. Brief report: hypercoagulable viscoelastic blood clot characteristics in critically-ill COVID-19 patients and associations with thrombotic complications. J Trauma Acute Care Surg. 2020;90:e7\u201312.","journal-title":"J Trauma Acute Care Surg"},{"key":"3437_CR9","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1056\/NEJMoa2103417","volume":"385","author":"EC Goligher","year":"2021","unstructured":"Goligher EC, Bradbury CA, McVerry BJ, REMAP-CAP Investigators, ACTIV-4a Investigators, ATTACC Investigators, et al. Therapeutic anticoagulation with heparin in critically Ill patients with Covid-19. N Engl J Med. 2021;385:777\u201389.","journal-title":"N Engl J Med"},{"key":"3437_CR10","doi-asserted-by":"publisher","first-page":"e779","DOI":"10.1016\/S2665-9913(20)30340-4","volume":"2","author":"G Zizzo","year":"2020","unstructured":"Zizzo G, Cohen PL. Imperfect storm: is interleukin-33 the achilles heel of COVID-19? Lancet Rheumatol. 2020;2:e779\u201390.","journal-title":"Lancet Rheumatol"},{"key":"3437_CR11","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1111\/j.1365-2044.2004.03757.x","volume":"59","author":"V Payne","year":"2004","unstructured":"Payne V, Kam PCA. Mast cell tryptase: a review of its physiology and clinical significance. Anaesthesia. 2004;59:695\u2013703.","journal-title":"Anaesthesia"},{"key":"3437_CR12","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1161\/CIRCULATIONAHA.120.050354","volume":"142","author":"CJ Lowenstein","year":"2020","unstructured":"Lowenstein CJ, Solomon SD. Severe COVID-19 is a microvascular disease. Circulation. 2020;142:1609\u201311.","journal-title":"Circulation"},{"key":"3437_CR13","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1136\/thoraxjnl-2020-215383","volume":"76","author":"BK Tan","year":"2021","unstructured":"Tan BK, Mainbourg S, Friggeri A, Bertoletti L, Douplat M, Dargaud Y, et al. Arterial and venous thromboembolism in COVID-19: a study-level meta-analysis. Thorax. 2021;76:970\u20139.","journal-title":"Thorax"},{"key":"3437_CR14","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.blre.2014.09.003","volume":"29","author":"JC Chapin","year":"2015","unstructured":"Chapin JC, Hajjar KA. Fibrinolysis and the control of blood coagulation. Blood Rev. 2015;29:17\u201324.","journal-title":"Blood Rev"},{"key":"3437_CR15","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1186\/s13054-020-03077-0","volume":"24","author":"T Iba","year":"2020","unstructured":"Iba T, Levy JH, Connors JM, Warkentin TE, Thachil J, Levi M. The unique characteristics of COVID-19 coagulopathy. Crit Care. 2020;24:360.","journal-title":"Crit Care"},{"key":"3437_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41569-021-00665-7","volume":"19","author":"DA Gorog","year":"2022","unstructured":"Gorog DA, Storey RF, Gurbel PA, Tantry US, Berger JS, Chan MY, et al. Current and novel biomarkers of thrombotic risk in COVID-19: a consensus statement from the international COVID-19 thrombosis biomarkers colloquium. Nat Rev Cardiol. 2022;19:1\u201321.","journal-title":"Nat Rev Cardiol"},{"key":"3437_CR17","doi-asserted-by":"publisher","first-page":"2215","DOI":"10.1111\/jth.15016","volume":"18","author":"C Nougier","year":"2020","unstructured":"Nougier C, Benoit R, Simon M, Desmurs-Clavel H, Marcotte G, Argaud L, et al. Hypofibrinolytic state and high thrombin generation may play a major role in SARS-COV2 associated thrombosis. J Thromb Haemost. 2020;18:2215\u20139.","journal-title":"J Thromb Haemost"},{"key":"3437_CR18","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1182\/blood.2020006520","volume":"136","author":"H Al-Samkari","year":"2020","unstructured":"Al-Samkari H, Karp Leaf RS, Dzik WH, Carlson JCTT, Fogerty AE, Waheed A, et al. COVID-19 and coagulation: bleeding and thrombotic manifestations of SARS-CoV-2 infection. Blood. 2020;136:489\u2013500.","journal-title":"Blood"},{"key":"3437_CR19","first-page":"247","volume-title":"Fibrinogen and fibrin","author":"JW Weisel","year":"2005","unstructured":"Weisel JW. Fibrinogen and fibrin. Cambridge, Massachusetts (USA): Academic Press Inc; 2005. p. 247\u201399."},{"key":"3437_CR20","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.jamcollsurg.2020.05.007","volume":"231","author":"FL Wright","year":"2020","unstructured":"Wright FL, Vogler TO, Moore EE, Moore HB, Wohlauer MV, Urban S, et al. Fibrinolysis shutdown correlation with thromboembolic events in severe COVID-19 Infection. J Am Coll Surg. 2020;231:193\u2013203.","journal-title":"J Am Coll Surg"},{"key":"3437_CR21","doi-asserted-by":"publisher","first-page":"e72","DOI":"10.1111\/j.1755-5922.2010.00171.x","volume":"28","author":"M Cesari","year":"2010","unstructured":"Cesari M, Pahor M, Incalzi RA. Plasminogen activator inhibitor-1 (PAI-1): a key factor linking fibrinolysis and age-related subclinical and clinical conditions. Cardiovasc Ther. 2010;28:e72.","journal-title":"Cardiovasc Ther"},{"issue":"8","key":"3437_CR22","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.1111\/j.1538-7836.2005.01420.x","volume":"3","author":"DE Vaughan","year":"2005","unstructured":"Vaughan DE. PAI-1 and atherothrombosis. J Thromb Haemost. 2005;3(8):1879\u201383.","journal-title":"J Thromb Haemost"},{"key":"3437_CR23","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1038\/s41598-020-80010-z","volume":"11","author":"Y Zuo","year":"2021","unstructured":"Zuo Y, Warnock M, Harbaugh A, Yalavarthi S, Gockman K, Zuo M, et al. Plasma tissue plasminogen activator and plasminogen activator inhibitor-1 in hospitalized COVID-19 patients. Sci Rep. 2021;11:1580.","journal-title":"Sci Rep"},{"key":"3437_CR24","doi-asserted-by":"publisher","first-page":"2701","DOI":"10.1016\/j.jacc.2009.11.095","volume":"55","author":"DA Gorog","year":"2010","unstructured":"Gorog DA. Prognostic value of plasma fibrinolysis activation markers in cardiovascular disease. J Am Coll Cardiol. 2010;55:2701\u20139.","journal-title":"J Am Coll Cardiol"},{"key":"3437_CR25","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1161\/01.CIR.96.3.761","volume":"96","author":"WL Chandler","year":"1997","unstructured":"Chandler WL, Alessi MC, Aillaud MF, Henderson P, Vague P, Juhan-Vague I. Clearance of tissue plasminogen activator (TPA) and TPA\/plasminogen activator inhibitor type 1 (PAI-1) complex. Circulation. 1997;96:761\u20138.","journal-title":"Circulation"},{"key":"3437_CR26","doi-asserted-by":"publisher","first-page":"106857","DOI":"10.1016\/j.vph.2021.106857","volume":"138","author":"R Ragusa","year":"2021","unstructured":"Ragusa R, Basta G, Del Turco S, Caselli C. A possible role for ST2 as prognostic biomarker for COVID-19. Vasc Pharmacol. 2021;138:106857.","journal-title":"Vasc Pharmacol"},{"key":"3437_CR27","doi-asserted-by":"publisher","first-page":"C1485","DOI":"10.1152\/ajpcell.00215.2005","volume":"289","author":"MC Meyer","year":"2005","unstructured":"Meyer MC, Creer MH, McHowat J. Potential role for mast cell tryptase in recruitment of inflammatory cells to endothelium. Am J Physiol Cell Physiol. 2005;289:C1485\u201391.","journal-title":"Am J Physiol Cell Physiol"},{"key":"3437_CR28","doi-asserted-by":"publisher","first-page":"3154","DOI":"10.4049\/jimmunol.165.6.3154","volume":"165","author":"SH Cho","year":"2000","unstructured":"Cho SH, Tam SW, Demissie-Sanders S, Filler SA, Oh CK. Production of plasminogen activator inhibitor-1 by human mast cells and its possible role in asthma. J Immunol. 2000;165:3154\u201361.","journal-title":"J Immunol"},{"key":"3437_CR29","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1007\/s10456-020-09762-6","volume":"24","author":"A Philippe","year":"2021","unstructured":"Philippe A, Chocron R, Gendron N, Bory O, Beauvais A, Peron N, et al. Circulating Von Willebrand factor and high molecular weight multimers as markers of endothelial injury predict COVID-19 in-hospital mortality. Angiogenesis. 2021;24:505\u201317.","journal-title":"Angiogenesis"},{"key":"3437_CR30","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1111\/jth.15191","volume":"19","author":"I Mancini","year":"2021","unstructured":"Mancini I, Baronciani L, Artoni A, Colpani P, Biganzoli M, Cozzi G, et al. The ADAMTS13-von Willebrand factor axis in COVID-19 patients. J Thromb Haemost. 2021;19:513\u201321.","journal-title":"J Thromb Haemost"},{"key":"3437_CR31","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1055\/s-0041-1727282","volume":"47","author":"EJ Favaloro","year":"2021","unstructured":"Favaloro EJ, Henry BM, Lippi G. Increased VWF and decreased ADAMTS-13 in COVID-19: creating a milieu for (Micro)thrombosis. Semin Thromb Hemost. 2021;47:400\u201318.","journal-title":"Semin Thromb Hemost"},{"key":"3437_CR32","doi-asserted-by":"publisher","first-page":"2819","DOI":"10.1182\/blood-2017-04-780825","volume":"130","author":"DM Coenen","year":"2017","unstructured":"Coenen DM, Mastenbroek TG, Cosemans JMEM. Platelet interaction with activated endothelium: mechanistic insights from microfluidics. Blood. 2017;130:2819\u201328.","journal-title":"Blood"},{"key":"3437_CR33","doi-asserted-by":"publisher","first-page":"H87","DOI":"10.1152\/ajpheart.00204.2021","volume":"322","author":"R Seth","year":"2022","unstructured":"Seth R, McKinnon TAJ, Zhang XF. Contribution of the von Willebrand factor\/ADAMTS13 imbalance to COVID-19 coagulopathy. Am J Physiol Heart Circ Physiol. 2022;322:H87-93.","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"3437_CR34","doi-asserted-by":"publisher","first-page":"e0188921","DOI":"10.1371\/journal.pone.0188921","volume":"12","author":"M Mussbacher","year":"2017","unstructured":"Mussbacher M, Schrottmaier WC, Salzmann M, Brostjan C, Schmid JA, Starlinger P, et al. Optimized plasma preparation is essential to monitor platelet-stored molecules in humans. PLoS\u00a0One. 2017;12:e0188921.","journal-title":"PLoS\u00a0One"},{"key":"3437_CR35","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1161\/CIRCRESAHA.120.317703","volume":"127","author":"Y Zaid","year":"2020","unstructured":"Zaid Y, Puhm F, Allaeys I, Naya A, Oudghiri M, Khalki L, et al. Platelets can associate with SARS-CoV-2 RNA and are hyperactivated in COVID-19. Circ Res. 2020;127:1404\u201318.","journal-title":"Circ Res"},{"key":"3437_CR36","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/1477-9560-11-7","volume":"11","author":"MM Prechel","year":"2013","unstructured":"Prechel MM, Walenga JM. Emphasis on the role of PF4 in the incidence, pathophysiology and treatment of heparin induced thrombocytopenia. Thromb J. 2013;11:7.","journal-title":"Thromb J"},{"key":"3437_CR37","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1111\/bjh.17273","volume":"192","author":"SE Ward","year":"2021","unstructured":"Ward SE, Curley GF, Lavin M, Fogarty H, Karampini E, McEvoy NL, et al. Von Willebrand factor propeptide in severe coronavirus disease 2019 (COVID-19): evidence of acute and sustained endothelial cell activation. Br J Haematol. 2021;192:714\u20139.","journal-title":"Br J Haematol"},{"key":"3437_CR38","doi-asserted-by":"publisher","first-page":"E468","DOI":"10.1002\/ajh.26372","volume":"96","author":"BG Fenyves","year":"2021","unstructured":"Fenyves BG, Mehta A, Kays KR, Beakes C, Margolin J, Team MC-19 C& P, et al. Plasma P-selectin is an early marker of thromboembolism in COVID-19. Am J Hematol. 2021;96:E468\u201371.","journal-title":"Am J Hematol"},{"key":"3437_CR39","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1182\/blood.2020007252","volume":"136","author":"ED Hottz","year":"2020","unstructured":"Hottz ED, Azevedo-Quintanilha IG, Palhinha L, Teixeira L, Barreto EA, P\u00e3o CRR, et al. Platelet activation and platelet-monocyte aggregate formation trigger tissue factor expression in patients with severe COVID-19. Blood. 2020;136:1330\u201341.","journal-title":"Blood"},{"key":"3437_CR40","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1161\/CIRCRESAHA.120.317803","volume":"127","author":"TJ Barrett","year":"2020","unstructured":"Barrett TJ, Lee AH, Xia Y, Lin LH, Black M, Cotzia P, et al. Platelet and vascular biomarkers associate with thrombosis and death in coronavirus disease. Circ Res. 2020;127:945\u20137.","journal-title":"Circ Res"},{"key":"3437_CR41","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1038\/s41577-021-00665-1","volume":"22","author":"B Afzali","year":"2022","unstructured":"Afzali B, Noris M, Lambrecht BN, Kemper C. The state of complement in COVID-19. Nat Rev Immunol. 2022;22:77\u201384.","journal-title":"Nat Rev Immunol"},{"key":"3437_CR42","doi-asserted-by":"publisher","first-page":"1752","DOI":"10.1111\/jth.14828","volume":"18","author":"J Wang","year":"2020","unstructured":"Wang J, Hajizadeh N, Moore EE, McIntyre RC, Moore PK, Veress LA, et al. Tissue plasminogen activator (tPA) treatment for COVID-19 associated acute respiratory distress syndrome (ARDS): a case series. J Thromb Haemost. 2020;18:1752\u20135.","journal-title":"J Thromb Haemost"},{"key":"3437_CR43","first-page":"710","volume":"161","author":"CD Barrett","year":"2021","unstructured":"Barrett CD, Moore HB, Moore EE, Wang J, Hajizadeh N, Biffl WL, et al. Study of alteplase for respiratory failure in SARS-CoV-2 COVID-19 (STARS): a vanguard multicenter, rapidly adaptive, pragmatic, randomized, controlled trial. SSRN Electron J. 2021;161:710\u201327.","journal-title":"SSRN Electron J"},{"key":"3437_CR44","first-page":"506","volume":"235","author":"M Verstraete","year":"1985","unstructured":"Verstraete M, Bounameaux H, de Cock F, Van de Werf F, Collen D. Pharmacokinetics and systemic fibrinogenolytic effects of recombinant human tissue-type plasminogen activator (rt-PA) in humans. J Pharmacol Exp Ther. 1985;235:506\u201312.","journal-title":"J Pharmacol Exp Ther"},{"key":"3437_CR45","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1053\/j.jvca.2019.05.035","volume":"34","author":"A Abdelaal Ahmed Mahmoud","year":"2020","unstructured":"Abdelaal Ahmed Mahmoud A, Mahmoud HE, Mahran MA, Khaled M. streptokinase versus unfractionated heparin nebulization in patients with severe acute respiratory distress syndrome (ARDS): a randomized controlled trial with observational controls. J Cardiothorac Vasc Anesth. 2020;34:436\u201343.","journal-title":"J Cardiothorac Vasc Anesth"},{"key":"3437_CR46","doi-asserted-by":"publisher","first-page":"3491","DOI":"10.1021\/jm049766q","volume":"47","author":"H Elokdah","year":"2004","unstructured":"Elokdah H, Abou-Gharbia M, Hennan JK, McFarlane G, Mugford CP, Krishnamurthy G, et al. Tiplaxtinin, a novel, orally efficacious inhibitor of plasminogen activator inhibitor-1: design, synthesis, and preclinical characterization. J Med Chem. 2004;47:3491\u20134.","journal-title":"J Med Chem"},{"key":"3437_CR47","doi-asserted-by":"publisher","first-page":"1482","DOI":"10.3390\/ijms22031482","volume":"22","author":"M Sillen","year":"2021","unstructured":"Sillen M, Miyata T, Vaughan DE, Strelkov SV, Declerck PJ. Structural insight into the two-step mechanism of PAI-1 inhibition by small molecule TM5484. Int J Mol Sci. 2021;22:1482.","journal-title":"Int J Mol Sci"},{"key":"3437_CR48","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1056\/NEJMoa1505533","volume":"374","author":"F Peyvandi","year":"2016","unstructured":"Peyvandi F, Scully M, Kremer Hovinga JA, Cataland S, Kn\u00f6bl P, Wu H, et al. Caplacizumab for acquired thrombotic thrombocytopenic purpura. N Engl J Med. 2016;374:511\u201322.","journal-title":"N Engl J Med"},{"key":"3437_CR49","doi-asserted-by":"publisher","first-page":"2455","DOI":"10.1177\/0962280218784726","volume":"28","author":"M van Smeden","year":"2019","unstructured":"van Smeden M, Moons KG, de Groot JA, Collins GS, Altman DG, Eijkemans MJ, et al. Sample size for binary logistic prediction models: beyond events per variable criteria. Stat Methods Med Res. 2019;28:2455\u201374.","journal-title":"Stat Methods Med Res"},{"key":"3437_CR50","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1007\/s10557-020-07084-9","volume":"35","author":"A G\u0105secka","year":"2021","unstructured":"G\u0105secka A, Borovac JA, Guerreiro RA, Giustozzi M, Parker W, Caldeira D, et al. Thrombotic complications in patients with COVID-19: pathophysiological mechanisms, diagnosis, and treatment. Cardiovasc Drugs Ther. 2021;35:215\u201329.","journal-title":"Cardiovasc Drugs Ther"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-022-03437-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12185-022-03437-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-022-03437-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,17]],"date-time":"2022-11-17T17:34:22Z","timestamp":1668706462000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12185-022-03437-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,22]]},"references-count":50,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["3437"],"URL":"https:\/\/doi.org\/10.1007\/s12185-022-03437-2","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2021.11.10.21266185","asserted-by":"object"}]},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,22]]},"assertion":[{"value":"3 February 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 July 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 August 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 August 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing financial interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}